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OBJECTIVE — To analyze the cost-effectiveness of bariatric surgery in severely obese (BMI
35 kg/m
2) adults who have diabetes, using a validated diabetes cost-effectiveness model.
RESEARCH DESIGN AND METHODS — We expanded the Centers for Disease Con-
trol and Prevention–RTI Diabetes Cost-Effectiveness Model to incorporate bariatric surgery. In
this simulation model, bariatric surgery may lead to diabetes remission and reductions in other
risk factors, which then lead to fewer diabetes complications and increased quality of life (QoL).
Surgery is also associated with perioperative mortality and subsequent complications, and pa-
tients in remission may relapse to diabetes. We separately estimate the costs, quality-adjusted
life-years(QALYs),andcost-effectivenessofgastricbypasssurgeryrelativetousualdiabetescare
and of gastric banding surgery relative to usual diabetes care. We examine the cost-effectiveness
ofeachtypeofsurgeryforseverelyobeseindividualswhoarenewlydiagnosedwithdiabetesand
for severely obese individuals with established diabetes.
RESULTS — In all analyses, bariatric surgery increased QALYs and increased costs. Bypass
surgery had cost-effectiveness ratios of $7,000/QALY and $12,000/QALY for severely obese
patients with newly diagnosed and established diabetes, respectively. Banding surgery had
cost-effectiveness ratios of $11,000/QALY and $13,000/QALY for the respective groups. In
sensitivity analyses, the cost-effectiveness ratios were most affected by assumptions about the
direct gain in QoL from BMI loss following surgery.
CONCLUSIONS — Our analysis indicates that gastric bypass and gastric banding are cost-
effectivemethodsofreducingmortalityanddiabetescomplicationsinseverelyobeseadultswith
diabetes.
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I
n recent years, bariatric surgery has
emerged as a popular treatment to re-
duce body weight and improve obesity-
related complications, particularly in the
diabetic population. Several studies have
shown that surgery can lead to signiﬁcant
weight loss, with excess body weight re-
duced by 50% (1,2). Although weight
loss declines over time, the Swedish
Obese Subjects (SOS) Study found signif-
icant weight loss even 10 years after sur-
gery(3,4).Inadditiontosustainedweight
loss, bariatric surgery may provide addi-
tional beneﬁts to people with diabetes.
Among severely obese patients with dia-
betes, bariatric surgery often leads to dia-
betes remission, with remission rates that
areashighas80%intheshortrun(1)and
that remain signiﬁcant in the long run
(3,4).
Although the evidence suggests that
bariatric surgery is a successful long-term
treatment of obesity for people with dia-
betes, it is an expensive procedure. The
average cost of surgery exceeds $13,000
(5), with additional costs possible in the
months following surgery (6). This raises
the question of whether bariatric surgery
is cost-effective for severely obese people
with diabetes.
Several studies have estimated the
cost-effectiveness of bariatric surgery
and found that surgery is either cost-
effective (7–10) or that it leads to cost
savings over time (6,11–13). The exist-
ing studies tend to be relatively simple,
and only two (10,13) focus on people
with diabetes. The studies generally do
not model the microvascular complica-
tions associated with diabetes, the ef-
fect of surgery on blood pressure and
cholesterol levels, or the resulting
outcomes.
This study used the Centers for Dis-
ease Control and Prevention (CDC)-RTI
Diabetes Cost-Effectiveness Model to an-
alyze the cost-effectiveness of bariatric
surgery in severely obese adults with dia-
betes. We separately estimated the cost-
effectiveness of gastric bypass surgery
relative to usual diabetes care and the
cost-effectiveness of gastric banding sur-
gery relative to usual diabetes care. Gas-
tric bypass and gastric banding are the
two forms of bariatric surgery most com-
monlystudied(1).Weexaminedthecost-
effectiveness of each type of surgery for
severely obese people who are newly di-
agnosed with diabetes (no more than 5
years after diagnosis) and for people with
establisheddiabetes(atleast10yearsafter
diagnosis).
RESEARCH DESIGN AND
METHODS— The CDC-RTI Diabe-
tes Cost-Effectiveness Model is a
Markov simulation model of disease
progression and cost-effectiveness for
type 2 diabetes that follows patients
from diagnosis to either death or age 95
years. The model simulates develop-
ment of diabetes-related complications
on three microvascular disease paths
(nephropathy, neuropathy, and reti-
nopathy) and two macrovascular dis-
ease paths (coronary heart disease
[CHD]andstroke).Modeloutcomesin-
clude disease complications, deaths,
costs, and quality-adjusted life-years
(QALYs). In the model, progression be-
tweendiseasestatesisgovernedbytran-
sition probabilities that depend on risk
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ventions affect the transition probabili-
ties and resulting complications. The
model has been used to estimate the
cost-effectiveness of interventions for
patientswithdiagnoseddiabetesorpre-
diabetes (14,15). Details about the
model and its validation are presented
elsewhere (14–16).
Bariatric surgery is incorporated in
the following ways. First, the model al-
lows for diabetes remission and improve-
ment, important results of bariatric
surgery. We deﬁned remission as normal
glycemic levels following surgery without
antidiabetes medications. This was incor-
porated in the model as no progression
along the microvascular paths, no diabe-
tes treatment costs, elimination of the di-
abetes indicator variable in the CHD and
stroke equations, and elimination of the
diabetes other-cause mortality multiplier.
We created an “improved diabetes” state
for people who reduced the use of antidia-
betes medications but did not achieve full
diabetes remission. The rates of diabetes re-
missionandimprovementfollowingbariat-
ricsurgeryproceduresareshowninTable1
with values based on a meta-analysis (1).
The reduction in costs for improvement is
based on two smaller studies (17,18). The
online appendix (available at http://care.
diabetesjournals.org/cgi/content/full/dc10-
0554/DC1) provides additional details on
sources and parameter derivation for the
variables described in this section.
Second,themodelincludesanannual
probability of relapse from remission to
diabetes.Becausefewstudiesexaminethe
long-term effects of bariatric surgery, we
focused on the SOS study, which fol-
lowed patients for 10 years after bariatric
surgery (3). We used the diabetes remis-
sion rates reported at 2 and 10 years to
calculate the probability of relapse in
Table 1.
Third,themodelaccountsforperiop-
erativemortalityandthelong-termeffects
of surgery on mortality. For perioperative
mortality, we used separate rates for by-
pass and banding surgery (19). The
model calculates future changes in mor-
tality based on surgery’s effects on blood
pressure, cholesterol, and the remission
or improvement of diabetes. We used
multiple literature sources to estimate the
effect of surgery on blood pressure and
cholesterolvalues.Remissionorimprove-
ment in diabetes stops or slows progres-
sion of diabetes complications, which
reduces mortality. For people in diabetes
remission, we also lowered other-cause
mortality to the baseline rate among peo-
ple with no diabetes. These effects are
listed in Table 1.
Fourth, the model includes the costs
of bariatric surgery. First-year bypass and
banding surgery costs are based on an
analysis of Medstat claims by Eric A.
Finkelstein et al. (2008, unpublished
data).Theanalysiscalculatedthecostsat-
tributable to surgery, including the sur-
gery costs and any complication costs in
the ﬁrst year. For costs in subsequent
years,weincludedcostsoffollow-upcare
visits;nutritionalsupplements;long-term
complications, such as revisional surgery,
cholelithiasis, abdominoplasty, and non-
operative leaks; and band removal (for
gastric banding). Table 1 lists the compli-
cation costs by year after surgery.
Finally, in addition to changes in
quality of life (QoL) following surgery
that result from reductions in diabetes
complications, the model includes
changes in QoL directly associated with
bariatric surgery. We included a change
in QoL associated with bariatric surgery
thatwastheproductofthechangeinutil-
ity for a 1–BMI unit change in weight and
the change in BMI associated with
surgery.
To analyze the cost-effectiveness of
bariatric surgery, we focused on the pop-
ulation with BMI 35 kg/m
2 and diabe-
tes. We deﬁned the characteristics of this
population by estimating the distribution
ofage,sex,race,hypertensionstatus,cho-
lesterol status, and smoking status as well
as systolic blood pressure, total choles-
terol, and HDL levels within the National
HealthandNutritionExaminationSurvey
for the subset of the obese population
(BMI 30 kg/m
2) with self-reported dia-
betes. Values for the population with BMI
35 kg/m
2 were similar, so we used data
from the full obese population with its
larger sample size.
Within the severely obese diabetic
population, we separately analyzed the
newly diagnosed diabetic population and
the established diabetic population. We
distinguished between these two groups
because studies have shown that surgery
leads to signiﬁcantly less weight loss and
lower rates of diabetes remission in peo-
plewithlongerdiabetesduration(17,18).
Theprimarydifferencesbetweenthepop-
ulations are that the newly diagnosed di-
abeticpopulationisyounger(aged35–74
years) than the established diabetic pop-
ulation (aged 45–74 years) to represent
the 10-year difference in duration, and
thediabetesremissionrateislowerforthe
established diabetic population (18). We
adjusted diabetes duration to 10 years in
the model to reﬂect changes in glycemic
control and complications in the estab-
lished diabetic population.
Using these two severely obese dia-
betic populations, we estimated the cost-
effectiveness of gastric bypass and gastric
banding surgery. The two surgeries differ
in several factors, including diabetes re-
mission rate, diabetes improvement rate,
perioperativemortalityrate,ﬁrst-yearand
following-year costs, and effect on blood
pressure, cholesterol, and QoL. Table 1
includes the speciﬁc parameter values for
each surgery type. For our baseline anal-
yses for each type of surgery, we com-
pared the surgery to usual diabetes care
that included tight glycemic control sim-
ilartothatprovidedintheUKProspective
DiabetesStudy(20).Weassumedthatpa-
tients who were not in diabetes remission
would also receive tight glycemic control.
In total, our baseline analyses included
four model runs, with separate runs for
each type of surgery and for each diabetic
population (newly diagnosed and
established).
We converted all costs to 2005 U.S.
dollars using the medical-care compo-
nent of the Consumer Price Index (21).
We discounted costs and QALYs by a 3%
annual rate, and we estimated incremen-
tal cost-effectiveness ratios that were
roundedtothenearest$1,000/QALY.We
also report undiscounted remaining
life-years.
We ran one-way sensitivity analyses
to determine how key factors affected the
cost-effectiveness ratios. When possible,
we used end points of the published 95%
(90% for surgery costs) CI of the model
parameter to determine upper and lower
values to input into the model. For most
parameters where CIs were unavailable,
we halved and doubled the baseline val-
ues.WevariedthechangeinQoLperunit
BMI change from 0 (i.e., surgery-related
weightlosshasnodirecteffectonQoL)to
0.017. We also analyzed the effect of sur-
gery on the diabetic population with a
BMI between 30 and 34 kg/m
2.W ea s -
sumed a similar percentage change in ex-
cess weight loss (22) as in our main
analysis, which leads to a smaller change
in BMI and QoL improvement.
To examine how conjoint parameter
uncertaintyaffectedthemodelresults,we
conducted probabilistic sensitivity analy-
sis (PSA) on key parameters involved in
estimating the cost-effectiveness ratios.
Applying distributions for surgery costs,
Cost-effectiveness of bariatric surgery
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Variable Bypass Banding Parameter value
Range for
sensitivity
analysis
Parameter values for people with newly diagnosed diabetes
Diabetes remission rate   80.3% 74.4–86.1%
  56.7% 46.7–66.8%
Glycemic level after remission    6.0%
Diabetes improvement rate   0.0%
  24.0% 19.8–28.3%
Glycemic level after improvement    5.9%
Reduction in oral medications usage due to diabetes improvement    51.8%
Annual probability of relapse    8.3%
Perioperative mortality rate   0.253% 0.143–0.365%
  0.068% 0.009–0.136%
Effect of surgery on systolic blood pressure   11.25% reduction ﬁrst 2 years
Effect then reduced by 1.4% each year
until no reduction in year 10
  3.2% reduction ﬁrst 2 years then
reduction to 0
Effect of surgery on total cholesterol   16.1% reduction ﬁrst 2 years
Effect then reduced by 1.2% each year
until no reduction in year 10
  5.0% reduction ﬁrst 2 years then
reduction to 0
Effect of surgery on HDL   No effect ﬁrst 2 years
Effect then increased by 1.7% each
year until year 10
  10.0% increase ﬁrst 2 years
Effect then decreased by 0.05% each
year until year 10
Effect of surgery on QoL (equals utility improvement per 1 unit
BMI decline times BMI loss following surgery)   0.0899 0–0.275
  0.0668 0–0.204
Mean utility improvement per 1 unit BMI decline    0.0056 0–0.017
Mean BMI loss following surgery   16.17 14.07–18.27
  12.01 10.78–13.24
Surgery and ﬁrst year costs   $23,871 $6,612–55,261
  $15,169 $2,857–30,186
Year 2 costs   $3,207 $1,603–6,414
Year 3 costs   $1,990 $995–3,981
Year 4 costs   $1,469 $734–2,938
Year 5 costs   $1,469 $734–2,938
Year 6 costs   $330 $165–661
Year 2 costs   $3,300 $1,650–6,600
Year 3 costs   $1,940 $970–3,880
Year 4 costs   $1,940 $970–3,880
Year 5 costs   $1,940 $970–3,880
Year 6 costs   $802 $401–1,604
Parameter values that differ for people with established diabetes
Diabetes remission rate    40% 37.2–43.1%
Diabetes improvement rate    40% 37.2–43.1%
Glycemic level after improvement    7.0%
Reduction in oral medication usage due to diabetes improvement    24.9% 12.45%
Reduction in insulin usage due to diabetes improvement    62.5% 31.25%
See online appendix for details on sources and parameter derivation.
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parameters (see online appendix), we
drew 1,000 parameter combinations and
ran the model separately for each combi-
nation for newly diagnosed patients un-
dergoingbypasssurgery.Werepeatedthe
process for newly diagnosed patients un-
dergoing banding surgery. Due to run
time constraints, we only looked at pa-
tients in the 45- to 54-year age-group,
which had a cost-effectiveness ratio that
wasclosetothecost-effectivenessratiofor
the entire population.
RESULTS— Based on the model as-
sumptions, bariatric surgery leads to dia-
betes remission, and the share of patients
inremissiondeclinesovertimeaspatients
relapse or die. Surgery also reduced the
incidence of many diabetes-related com-
plications for people with newly diag-
nosed diabetes (see online appendix).
Ineachofourmainanalyses,bariatric
surgery had cost-effectiveness ratios be-
tween $7,000 and $13,000/QALY. Table
2showstotalcosts,life-years,QALYs,and
cost-effectiveness ratios (cost/QALY
gained) by surgery type and patient
group. Within the newly diagnosed dia-
betic population, gastric bypass led to
1.72 life-years gained, 2.21 QALYs
gained, and a cost-effectiveness ratio of
$7,000/QALY;gastricbandingledto1.14
life-yearsgained,1.57QALYsgained,and
a cost-effectiveness ratio of $11,000/
QALY. Relative to the newly diagnosed
diabetic population, bariatric surgery led
to fewer life-years gained and higher in-
cremental cost-effectiveness ratios within
the established diabetic population. Gas-
tric bypass led to 1.09 life-years gained,
1.70 QALYs gained, and a cost-
effectiveness ratio of $12,000/QALY,
whereas gastric banding led to 0.94 life-
years gained, 1.34 QALYs gained, and a
cost-effectiveness ratio of $13,000/QALY
in the established diabetic population.
One-way sensitivity analyses
Fig. 1 shows the effect on the cost-
effectiveness ratio of varying each param-
eter in one-way sensitivity analyses. The
ﬁgure includes separate panels for each
baseline analysis group (i.e., bypass and
banding surgery for the newly diagnosed
and established diabetic populations).
For each analysis population, varying the
effects of surgery on remission rates, peri-
operative mortality, and relapse rate had
relatively small effects on the cost-
effectivenessratios.Varyingthechangein
BMIfromsurgeryalsohadlittleeffect,but
varying the direct QoL improvement per
unit of BMI loss from 0.017 (which re-
duces the cost-effectiveness ratio) to 0
(whichincreasesthecost-effectivenessra-
tio) had the biggest impact on the cost-
effectiveness ratios. Doubling the cost of
tight glycemic control (i.e., increasing the
cost of treating active diabetes) produces
the lowest or second lowest cost-
effectiveness ratio in each analysis popu-
lation. Varying surgery costs had a bigger
impact on the bypass cost-effectiveness
ratios than on the banding ratios, while
varying follow-up costs had a bigger im-
pact on the banding cost-effectiveness ra-
tiosthanonthebypassratios.Halvingthe
reduction in medication usage associated
with diabetes improvement increased the
cost-effectiveness ratios by $1,000/
QALY for each analysis population (not
shown).
In addition, we ran analyses for dif-
ferent subpopulation groups. Running
theanalysisforadiabeticpopulationwith
a BMI of 30–34 kg/m
2 approximately
doubled the cost-effectiveness ratios, due
primarily to the lower BMI loss and con-
sequentlysmallerchangeinQoL.Wealso
ran analyses with each 10-year age-group
(notshown).Withinthenewlydiagnosed
diabeticpopulation,cost-effectivenessra-
tios ranged from $5,000/QALY at ages
35–44 years to $12,000/QALY at ages
65–74 years for bypass surgery and from
$9,000 to $17,000/QALY for the same
ages for banding surgery. Within the es-
tablished diabetic population, cost-
effectiveness ratios ranged from $9,000/
QALY at ages 45–54 years to $18,000/
QALY at ages 65–74 years for bypass
surgery and from $11,000 to $19,000/
QALY for the same ages for banding sur-
gery. The age-group analyses assumed
(due to lack of age-speciﬁc data) that re-
mission, perioperative mortality, and
other direct surgical outcome rates and
costs did not vary by age. Therefore, the
age-group results were driven by higher
mortality rates in older populations.
PSA
For bypass surgery, the median cost-
effectiveness ratio for the 1,000 simula-
tions on newly diagnosed patients aged
45–54 years was $6,000/QALY, and 95%
of the values fell between $2,000 and
$23,000/QALY. All simulations with a
negative cost-effectiveness ratio had
lower costs and higher QALYs. For band-
ing, the median cost-effectiveness ratio
for the 1,000 simulations was $10,000/
QALY, and 95% of the estimates fell be-
tween just under $0 and $30,000/QALY.
Again, all simulations with a negative
cost-effectiveness ratio had lower costs
and higher QALYs. For detailed PSA re-
sults, including cost-effectiveness accept-
ability curves, see the online appendix.
CONCLUSIONS — Overall, we ﬁnd
that gastric bypass and gastric banding
appeartoberelativelycost-effectivetreat-
ments in the severely obese diabetic pop-
ulation, with cost-effectiveness ratios
ranging from $7,000 to $13,000/QALY.
These cost-effectiveness ratios are lower
than the cost-effectiveness ratios for com-
monly applied diabetes interventions and
well below the $50,000/QALY bench-
mark sometimes applied (23) as a mea-
Table 2—Life-years gained and cost-effectiveness ratios (relative to no surgery) for baseline
analyses
Total
costs*
Remaining
life-years QALYs*
Cost-effectiveness
ratio ($/QALY)†
Patients with newly diagnosed diabetes
No surgery (standard care) $71,130 21.62 9.55
Bypass surgery $86,665 23.34 11.76
Incremental (vs. no surgery) $15,536 1.72 2.21 $7,000
Banding surgery $89,029 22.76 11.12
Incremental (vs. no surgery) $17,900 1.14 1.57 $11,000
Patients with established diabetes
No surgery $79,618 16.86 7.68
Bypass surgery $99,944 17.95 9.38
Incremental (vs. no surgery) $20,326 1.09 1.70 $12,000
Banding surgery $96,921 17.80 9.02
Incremental (vs. no surgery) $17,304 0.94 1.34 $13,000
*Costs and QALYs are discounted at a 3% annual rate. †Cost-effectiveness ratios are rounded to the nearest
$1,000/QALY.
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health interventions. The cost-effective-
ness ratios are lower for the newly diag-
nosed diabetic population than for the
established diabetic population because
the diabetes remission rate is higher for
those newly diagnosed.
Althoughourcost-effectivenessratios
are in a similar range as several studies
that found that bariatric surgery increases
costs and QALYs (7–10), we do not ﬁnd
cost savings from either gastric bypass or
gastric banding surgery as several other
studies have reported (6,11–13). There
are at least three reasons why we did not
ﬁnd cost savings. First, the two cost-
effectivenessmodelsthatﬁndcostsavings
(11,13)aresetoutsideoftheU.S.Because
our model reﬂects U.S. treatment costs,
our results may not be comparable.
Second, neither U.S.-based study that
found cost savings (6,12) used a cost-
effectiveness model. One study (6) com-
pared total costs for a surgery population
and a nonsurgery population; it assumed
thatanycostdifferenceswereattributable
to surgery and that savings in the years
following surgery would persist. The sec-
ond study (12) estimated cost differences
related to BMI in cross-sectional data and
then calculated the effect of surgery on
costsbasedonthedecreaseinBMIfollow-
ing surgery. It also assumed that cost re-
ductions after surgery would persist. We
explicitly model relapse to diabetes,
which leads to decreasing cost savings
over time. Third, our approach only in-
cludes diabetes-related costs that are
savedasaresultofdiabetesremissionand
the reduction of micro- and macrovascu-
lar complications; this could result in
lower savings than those found by the
two U.S. studies, which considered all
obesity-related costs.
In our analysis, bypass surgery leads
to greater gains in QALYs and has lower
costs than banding surgery for patients
with newly diagnosed diabetes. The prin-
cipal parameters that led to this result are
the higher diabetes remission rate in by-
pass surgery and the larger BMI loss and
therefore larger QoL improvement asso-
ciated with bypass surgery. The two pa-
rameters favoring banding surgery—
bypass surgery has higher ﬁrst-year costs
and higher perioperative mortality—do
not offset the parameters favoring bypass
surgery.Thedifferenceincost-effectiveness
ratios between the two surgeries is less pro-
nounced in the established diabetic popu-
lation than in the newly diagnosed diabetic
population.Intheestablisheddiabeticpop-
ulation, bypass and banding were assumed
to have the same rates of remission and
improvement.
Although the model parameters ap-
pear to favor bypass surgery, there have
not been direct trials of the two types of
surgeries. The more favorable bypass sur-
gery parameters may be due to the differ-
ent characteristics of people who opt for
bypass surgery. This population tends to
have a higher initial BMI and a greater
prevalence of comorbidities (1). A ran-
domized trial comparing bypass and
banding would provide more compelling
evidenceontherelativecost-effectiveness
ofthetwoproceduresthanoursimulation
provides.
Current National Institutes of Health
(24) guidelines state that patients with a
BMI 40 kg/m
2 or a BMI between 35 and
40 kg/m
2 plus a comorbidity such as dia-
betes may be candidates for bariatric sur-
gery. Most key model parameters are
based on surgery for extremely obese in-
dividuals (in a key meta-analysis [1], the
mean BMI is 47.9). One study (25), how-
Figure 1—Sensitivity analyses: cost-effectiveness ratios for lower and upper bound of input
values. The range of cost-effectiveness ratios after varying input parameters. For example, using
the 95% CI values of remission for bariatric surgery in newly diagnosed patients, we ﬁnd cost-
effectiveness ratios ranging from $6,000 to $8,000/QALY. A QoL improvement of 0.017 leads to a
lower cost-effectiveness ratio, and an improvement of 0 leads to a higher cost-effectiveness ratio.
Doubling tight glycemic control costs leads to a lower cost-effectiveness ratio, and halving them
leads to a higher cost-effectiveness ratio.
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missioninpeoplewithrelativelylowBMI.
In our sensitivity analysis for people with
a BMI between 30 and 34 kg/m
2, we esti-
mated higher cost-effectiveness ratios
than those for more obese patients, but
the ratios are still reasonably attractive.
Our analysis has several limitations.
First, our model is limited by the health
parameters included in the model. We
only measure the beneﬁts of bariatric sur-
gery arising from its effect on diabetes re-
mission, blood pressure, and cholesterol
levels—which in turn affect diabetes mi-
cro- and macrovascular complications—
and the effect of BMI loss on QoL. These
beneﬁtsincludereducedratesofcoronary
heart disease and stroke, important driv-
ers of morbidity and mortality in people
with diabetes. Second, limited data are
available on the long-term effects of bari-
atric surgery. Sensitivity analyses on the
diabetes remission rate and diabetes re-
lapse rate—two important long-term ef-
fects—suggest that varying these
parameters may not change the general
conclusion that bariatric surgery is cost-
effective. More broadly, the long-term
impacts of surgery on diabetes
complications, costs, and QALYs are gen-
eratedbyoursimulationmodel.Thereare
little or no direct data on surgery’s long-
term impact on these variables. In the
absence of long-term study data, a
simulation model may provide policy
makers with useful information about the
possible effects of interventions. Third,
we assumed a QoL improvement directly
associated with BMI loss based on cross-
sectional data due to limited data on
QALYs per BMI unit loss following sur-
gery. Fourth, few studies examine diabe-
tes remission in the population with
longer-term diabetes. Based on a single
study (18), we assumed rates of 40% re-
mission and 40% improvement for by-
pass and banding in the established
diabetic population.
Fifth, data on surgical outcomes for
patientswithestablisheddiabetesarelim-
ited. We incorporated lower rates of re-
mission in established patients in our
analysis, but we assumed (due to lack of
data) that surgical costs and perioperative
mortality rates were the same for estab-
lished patients as for newly diagnosed pa-
tients. If the outcomes are less favorable
for established patients, their cost-
effectiveness ratios would increase. Data
on surgical outcomes for older patients
are also limited, with similar implications
for the cost-effectiveness ratios.
Finally, our model assumes that dia-
betesprogressionratesarehomogeneous,
in the sense that a severely obese person
with active diabetes and an A1C of 8.0%
has the same progression rates for diabe-
tes complications as a nonobese person
with active diabetes and an A1C of 8.0%.
This assumption is reasonable given cur-
rent evidence, but it ignores alternative
possibilities.
Subject to these limitations, our anal-
ysis indicates that gastric bypass and gas-
tric banding surgery appear to provide a
cost-effective method of reducing mortal-
ity and diabetes complications in severely
obese adults with diabetes. We do not
ﬁnd that bariatric surgery is cost-saving.
Therefore, health care costs will increase
if more individuals receive bariatric sur-
gery, but the increased costs appear to
offer good value. As trials directly com-
paring bypass and banding surgery
emerge and more studies examine the
long-term effects of bariatric surgery, es-
timatesofthecost-effectivenessofsurgery
can become more ﬁne tuned, helping to
guide future policy decisions.
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